Sangamo Therapeutics, Inc (SGMOQ) stock
SGMOQOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.10−0.01 (-8.17%)
Close on Oct 19, 2026Market cap $39.43MP/E –Yield –
Sangamo Therapeutics profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Sangamo Therapeutics's profit margin for the twelve months ending Mar 31, 2026 was -356.9%. For fiscal 2025 it was -310.8%, against -169.4% the year before. The highest annual figure on record is -57.6% in fiscal 2014.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -310.8% | −141.4 |
| FY2024 | Dec 31, 2024 | -169.4% | −23.1 |
| FY2023 | Dec 31, 2023 | -146.3% | +26.5 |
| FY2022 | Dec 31, 2022 | -172.8% | −11.7 |
| FY2021 | Dec 31, 2021 | -161.1% | −58.7 |
| FY2020 | Dec 31, 2020 | -102.4% | −9.4 |
| FY2019 | Dec 31, 2019 | -92.9% | −12.0 |
| FY2018 | Dec 31, 2018 | -80.9% | +68.3 |
| FY2017 | Dec 31, 2017 | -149.2% | +220.4 |
| FY2016 | Dec 31, 2016 | -369.6% | −266.6 |
| FY2015 | Dec 31, 2015 | -102.9% | −45.4 |
| FY2014 | Dec 31, 2014 | -57.6% | +52.7 |
| FY2013 | Dec 31, 2013 | -110.3% | −7.5 |
| FY2012 | Dec 31, 2012 | -102.8% | +243.6 |
| FY2011 | Dec 31, 2011 | -346.4% | −227.0 |
| FY2010 | Dec 31, 2010 | -119.5% | −35.7 |
| FY2009 | Dec 31, 2009 | -83.8% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q1 FY2026 | Mar 31, 2026 | -2149.4% | −1674.1 |
| Q4 FY2025 | Dec 31, 2025 | -263.0% | +46.8 |
| Q3 FY2025 | Sep 30, 2025 | -6012.0% | −6033.6 |
| Q2 FY2025 | Jun 30, 2025 | -109.2% | +10039.1 |
| Q1 FY2025 | Mar 31, 2025 | -475.3% | +9730.3 |
| Q4 FY2024 | Dec 31, 2024 | -309.8% | +2642.9 |
| Q3 FY2024 | Sep 30, 2024 | 21.6% | +1130.0 |
| Q2 FY2024 | Jun 30, 2024 | -10148.3% | −8473.0 |
| Q1 FY2024 | Mar 31, 2024 | -10205.6% | −10219.0 |
| Q4 FY2023 | Dec 31, 2023 | -2952.7% | −2761.9 |
| Q3 FY2023 | Sep 30, 2023 | -1108.4% | −907.5 |
| Q2 FY2023 | Jun 30, 2023 | -1675.3% | −1528.3 |
| Q1 FY2023 | Mar 31, 2023 | 13.4% | +169.2 |
| Q4 FY2022 | Dec 31, 2022 | -190.9% | −56.9 |
| Q3 FY2022 | Sep 30, 2022 | -200.9% | −33.9 |
| Q2 FY2022 | Jun 30, 2022 | -147.0% | +22.3 |
| Q1 FY2022 | Mar 31, 2022 | -155.8% | +19.0 |
| Q4 FY2021 | Dec 31, 2021 | -134.0% | +23.4 |
| Q3 FY2021 | Sep 30, 2021 | -167.0% | −164.3 |
| Q2 FY2021 | Jun 30, 2021 | -169.2% | −2.5 |
| Q1 FY2021 | Mar 31, 2021 | -174.8% | +153.4 |
| Q4 FY2020 | Dec 31, 2020 | -157.4% | −165.7 |
| Q3 FY2020 | Sep 30, 2020 | -2.7% | +121.7 |
| Q2 FY2020 | Jun 30, 2020 | -166.7% | +5.9 |
| Q1 FY2020 | Mar 31, 2020 | -328.2% | +194.1 |
| Q4 FY2019 | Dec 31, 2019 | 8.3% | +77.9 |
| Q3 FY2019 | Sep 30, 2019 | -124.4% | −69.9 |
| Q2 FY2019 | Jun 30, 2019 | -172.6% | −94.9 |
| Q1 FY2019 | Mar 31, 2019 | -522.2% | −362.5 |
| Q4 FY2018 | Dec 31, 2018 | -69.5% | +30.6 |
| Q3 FY2018 | Sep 30, 2018 | -54.5% | +50.1 |
| Q2 FY2018 | Jun 30, 2018 | -77.7% | +73.7 |
| Q1 FY2018 | Mar 31, 2018 | -159.7% | +325.9 |
| Q4 FY2017 | Dec 31, 2017 | -100.1% | +7.8 |
| Q3 FY2017 | Sep 30, 2017 | -104.6% | +567.2 |
| Q2 FY2017 | Jun 30, 2017 | -151.4% | +566.5 |
| Q1 FY2017 | Mar 31, 2017 | -485.6% | – |
| Q4 FY2016 | Dec 31, 2016 | -107.9% | – |
| Q3 FY2016 | Sep 30, 2016 | -671.8% | – |
| Q2 FY2016 | Jun 30, 2016 | -717.9% | – |
See a number that looks wrong?